title: Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trial.
abstract: We examined the safety and efficacy of the docetaxel/cisplatin combination in patients with advanced, previously untreated NSCLC and evaluated changes in quality of life over time. Docetaxel was administered before cisplatin (both 75 mg/m2, 1-hour infusions) every 3 weeks to 47 patients with stage IIIB or stage IV NSCLC. Patients also received premedication of oral dexamethasone. The median age (range) of patients was 62 (45-78) years and 26 patients (55.3%) had adenocarcinoma. Of the 40 patients evaluable for response, one achieved a complete response and 14 had partial responses; the response rate was 37.5% (95% confidence intervals; 22.5, 52.5). In the intent-to-treat population the overall response rate was 31.9%. Time to response ranged from 3 to 20 weeks, and the median duration of response was 34.6 weeks. Median survival and median time to progression were 11.3 months and 18.9 weeks, respectively. One-year survival was 40%. Grade 3 or 4 neutropenia and febrile neutropenia were observed in 74.4% and 12.8% of patients, respectively. Severe asthenia was seen in 14.9% of patients. Other grade 3 or 4 toxicities included nausea (eight patients), vomiting (five), neurosensory effects (six), neuromotor effects (five), diarrhea (four), and infection (three). There was an improvement in emotional well-being; however, the overall quality of life score did not change with treatment. Docetaxel administered in combination with cisplatin is an active regimen in patients with NSCLC. This regimen of docetaxel (75 mg/m2) and cisplatin (75 mg/m2) repeated at 3-week intervals is being evaluated in an ongoing Eastern Cooperative Oncology Group (ECOG) randomized study in patients with advanced and metastatic NSCLC.
authors.affiliation: University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA. belanicp@msx.upmc.edu
authors.forename: C P
authors.initials: CP
authors.lastname: Belani
authors.forename: P
authors.initials: P
authors.lastname: Bonomi
authors.forename: T W
authors.initials: TW
authors.lastname: Dobbs
authors.forename: R F
authors.initials: RF
authors.lastname: DeVore
authors.forename: D S
authors.initials: DS
authors.lastname: Ettinger
authors.forename: J
authors.initials: J
authors.lastname: Jett
authors.forename: J D
authors.initials: JD
authors.lastname: Luketich
authors.forename: L J
authors.initials: LJ
authors.lastname: Cohen
authors.forename: D H
authors.initials: DH
authors.lastname: Johnson